Accès gratuit
Numéro
Med Sci (Paris)
Volume 30, Numéro 6-7, Juin–Juillet 2014
Page(s) 683 - 687
Section Forum
DOI https://doi.org/10.1051/medsci/20143006021
Publié en ligne 11 juillet 2014
  1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011 ; 144 : 646–674. [CrossRef] [PubMed] [Google Scholar]
  2. Bozic I, Antal T, Ohtsuki H, et al. Accumulation of driver and passenger mutations during tumour progression. Proc Natl Acad Sci USA 2010 ; 107 : 18545–18550. [CrossRef] [Google Scholar]
  3. Versteeg R. Cancer: tumours outside the mutation box. Nature 2014 ; 506 : 438–439. [CrossRef] [PubMed] [Google Scholar]
  4. Sakaguchi H, Okuno Y, Muramatsu H, et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet 2013 ; 45 : 937–941. [CrossRef] [PubMed] [Google Scholar]
  5. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013 ; 502 : 333–339. [CrossRef] [PubMed] [Google Scholar]
  6. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature 2013 ; 500 : 415–421. [CrossRef] [PubMed] [Google Scholar]
  7. Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014 ; 505 : 495–501. [CrossRef] [PubMed] [Google Scholar]
  8. Nik-Zainal S, Alexandrov LB, Wedge DC, et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012 ; 149 : 979–993. [CrossRef] [PubMed] [Google Scholar]
  9. Stephens PJ, Greenman CD, Fu B, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011 ; 144 : 27–40. [CrossRef] [PubMed] [Google Scholar]
  10. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res 1988 ; 48 : 7067–7071. [PubMed] [Google Scholar]
  11. Luebeck EG. Cancer: genomic evolution of metastasis. Nature 2010 ; 467 : 1053–1055. [CrossRef] [PubMed] [Google Scholar]
  12. Wong TN, Ramsingh G, Young A, et al. The role of early TP53 mutations on the evolution of therapy-related AML. 55th ASH Annual Meeting, New Orleans, December 7–10, 2013, abstract 5. [Google Scholar]
  13. Breen MS, Kemena C, Vlasov PK, et al. Epistasis as the primary factor in molecular evolution. Nature 2012 ; 490 : 535–538. [CrossRef] [PubMed] [Google Scholar]
  14. Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene 2013 ; 32 : 2601–2613. [CrossRef] [PubMed] [Google Scholar]
  15. Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012 ; 366 : 1079–1089. [CrossRef] [PubMed] [Google Scholar]
  16. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012 ; 483 : 100–103. [CrossRef] [PubMed] [Google Scholar]
  17. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013 ; 152 : 714–726. [CrossRef] [PubMed] [Google Scholar]
  18. Itzykson R, Kosmider O, Renneville A, et al. Clonal architecture of chronic myelomonocytic leukemias. Blood 2013 ; 121 : 2186–2198. [CrossRef] [PubMed] [Google Scholar]
  19. Anderson K, Lutz C, van Delft FW, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011 ; 469 : 356–361. [CrossRef] [PubMed] [Google Scholar]
  20. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature 2013 ; 501 : 328–337. [CrossRef] [PubMed] [Google Scholar]
  21. Clappier E, Gerby B, Sigaux F, et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med 2011 ; 208 : 653–661. [CrossRef] [PubMed] [Google Scholar]
  22. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002 ; 100 : 1014–1018. [CrossRef] [PubMed] [Google Scholar]
  23. Klco JM, Spencer DH, Miller CA, et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 2014 ; 25 : 379–392. [CrossRef] [PubMed] [Google Scholar]
  24. Diaz LA, Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014 ; 32 : 579–586. [CrossRef] [PubMed] [Google Scholar]
  25. Krebs MG, Metcalf RL, Carter L, et al. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol 2014 ; 11 : 129–144. [CrossRef] [PubMed] [Google Scholar]
  26. Jamal-Hanjani M, Thanopoulou E, Peggs KS, et al. Tumour heterogeneity and immune-modulation. Curr Opin Pharmacol 2013 ; 13 : 497–503. [CrossRef] [PubMed] [Google Scholar]
  27. Jan M, Snyder TM, Corces-Zimmerman MR, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 2012 ; 4 : 149ra118. [PubMed] [Google Scholar]
  28. Solary E, Bernard OA, Tefferi A, et al. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia 2014 ; 28 : 485–496. [CrossRef] [PubMed] [Google Scholar]
  29. Jacobs KB, Yeager M, Zhou W, et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet 2012 ; 44 : 651–658. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.